Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia.
about
Vitamin D Levels in Different Severity Groups of Schizophrenia.Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study.Is Mania the Hypertension of the Mood? Discussion of A Hypothesis.Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease.Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis.QT and QTc in Male Patients with Psychotic Disorders Treated with Atypical Neuroleptics.
P2860
Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Minimizing cardiovascular adve ...... n patients with schizophrenia.
@en
Minimizing cardiovascular adve ...... n patients with schizophrenia.
@nl
type
label
Minimizing cardiovascular adve ...... n patients with schizophrenia.
@en
Minimizing cardiovascular adve ...... n patients with schizophrenia.
@nl
prefLabel
Minimizing cardiovascular adve ...... n patients with schizophrenia.
@en
Minimizing cardiovascular adve ...... n patients with schizophrenia.
@nl
P2860
P356
P1476
Minimizing cardiovascular adve ...... n patients with schizophrenia.
@en
P2093
Fadi T Khasawneh
Gollapudi S Shankar
P2860
P304
P356
10.1155/2014/273060
P577
2014-02-04T00:00:00Z